Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of aloperine serving as drug for treating myocardial hypertrophy

A technology of cardiac hypertrophy and aloperine, which is applied in the direction of drug combinations, medical preparations containing active ingredients, and pharmaceutical formulas, can solve the problems of cardiac hypertrophy without literature reports, and achieve the goal of reducing ADMA levels, reducing content, and improving activity Effect

Active Publication Date: 2015-09-09
NINGXIA MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no literature report on the mechanism of aloperine in inhibiting myocardial hypertrophy in China.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of aloperine serving as drug for treating myocardial hypertrophy
  • Application of aloperine serving as drug for treating myocardial hypertrophy
  • Application of aloperine serving as drug for treating myocardial hypertrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Aloperine is used as a drug for the treatment of cardiac hypertrophy, wherein the molecular structural formula of aloperine is as shown in formula (1):

[0025]

[0026] The single application dose of aloperine in rats is 10 mg / kg body weight, and the dosage form of the medicine is a pharmaceutically allowed powder injection dosage form.

Embodiment 2

[0028] Aloperine is used as a drug for the treatment of cardiac hypertrophy, wherein the molecular structural formula of aloperine is as shown in formula (1):

[0029]

[0030] The single application dose of aloperine in rats is 20 mg / kg body weight, and the dosage form of the medicine is an injection dosage form allowed in pharmacy.

Embodiment 3

[0032] Aloperine is used as a drug for the treatment of cardiac hypertrophy, wherein the molecular structural formula of aloperine is as shown in formula (1):

[0033]

[0034] The single application dose of aloperine in rats is 40 mg / kg body weight, and the dosage form of the medicine is an oral dosage form allowed in pharmacy.

[0035] The effect of embodiment 1-3 can be verified by following animal experiments:

[0036] 1 Experimental materials

[0037] 1.1 Animals

[0038] Spargue-Dawley (SD) rats, weighing 280-320 g, were provided by the Animal Experiment Center of Ningxia Medical University.

[0039] 1.2 Drugs, reagents and instruments

[0040] Aloperine powder (Ningxia Zijinhua Pharmaceutical Co., Ltd., purity 99%); isoproterenol; cTnI and ADMA kits; SOD, GSH-PX and MDA kits; low-temperature high-speed centrifuge; standard instrument.

[0041] 1.3 Preparation of medicine

[0042] Preparation of 0.5% sodium carboxymethylcellulose (CMC) solution: Weigh 2.5 g of C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Melting pointaaaaaaaaaa
Login to View More

Abstract

The invention discloses application of aloperine serving as a drug for treating myocardial hypertrophy. Due to the fact that a rat myocardial hypertrophy model is established, the protecting effect and the mechanism of the aloperine on rat myocardial hypertrophy are explored and researched. An experiment result shows that when the aloperine is used within the safety dosage range, certain dosage-drug function relevance is shown when the dosage is 40 mg / kg, the heart weight, the left ventricle weight, the whole ventricle mass / the body mass and the left ventricle mass / the body mass can be remarkably improved, myocardial fibrosis is remarkably inhibited, cardiomyocyte hypertrophy and cardiomyocyte necrosis are reduced, myocardial compliance and the left ventricle diastole function are improved, myocardial contractility is improved, the serum NO concentration is improved, SOD activity and GSH-Px activity are improved, the ADMA level is reduced, the cTn-I content and the MDA content are reduced, the body oxidation resistance is improved, the lipid peroxidation level is reduced, and it is shown that the aloperine has the function of treating the myocardial hypertrophy.

Description

technical field [0001] The invention relates to the application of aloperine (Aloperine, ALO), in particular to the application of aloperine as a drug for treating myocardial hypertrophy. Background technique [0002] Cardiac hypertrophy is the adaptive response of the heart to adapt to various mechanical and neurohormonal stimuli. During the compensatory phase, the heart improves its pumping function by increasing the work output of the cardiomyocytes. But as the overload persists, this compensatory mechanism can develop into decompensated myocardial hypertrophy, leading to heart failure. The pathological changes of cardiac hypertrophy include the hypertrophy of cardiomyocytes and the proliferation and differentiation of fibroblasts, which are manifested as the increase of heart volume and mass. [0003] Nitric oxide (NO) is a vasodilator factor synthesized and released by vascular endothelial cells. It is formed with L-arginine as a substrate and catalyzed by nitric oxid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4748A61P9/00A61P9/04
Inventor 周茹郑婕郝银菊姚婉霞徐清斌张鹏汪静杜娟吴淑霞戴贵东
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com